WebMar 20, 2024 · positioned for growth. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living … [email protected] 781.786.8230 781.786.8230 linkedin.com twitter.com … [email protected] 781.786.8230 781.786.8230 linkedin.com twitter.com … Amy Reilly. Senior Vice President, Corporate Communications & Investor … WebFind company research, competitor information, contact details & financial data for Dyne Inc of Opp, AL. Get the latest business insights from Dun & Bradstreet.
Dyne Therapeutics Inc Ordinary Shares DYN Stock Quote
WebApr 7, 2024 · Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like ... WebOct 31, 2024 · DYNE-251 is Dyne’s product candidate being developed for people living with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. DYNE-251 consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1) which is highly expressed … how to travel to jerusalem
Dyne Therapeutics, Inc. (DYN) Stock Price Today, Quote & News
WebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The … WebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24. WebMay 16, 2024 · The new data being presented during ASGCT evaluated monthly repeat doses of DYNE-101 in an innovative hTfR1/DMSXL mouse model developed by Dyne and in non-human primates (NHPs). The hTfR1/DMSXL model expresses the human transferrin 1 receptor (TfR1) and carries a human DMPK gene with more than 1,000 CTG repeats … order of phases of the moon